Investigational drugs reduce risk of death from Ebola virus disease

(NIH/National Institute of Allergy and Infectious Diseases) The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news